Mean Platelet Volume/platelet Count Ratio As a Predictor of Long-term Mortality After Non-ST-elevation Myocardial Infarction
Overview
Authors
Affiliations
Previous studies reported an association between elevated mean platelet volume (MPV) and post-myocardial infarction mortality. This study explores the association between long-term mortality after non-ST-segment elevation myocardial infarction (NSTEMI) and the peripheral blood platelet indices (i.e., the mean platelet volume (MPV), platelet count, and the MPV/platelet (MPV/P) ratio). Two physicians independently reviewed the data of 619 NSTEMI patients. The blood samples were drawn and analyzed within 1 h of admission, the second, and the last hospital days. Patients were stratified into equal tertiles according to the platelet count, MPV, and MPV/platelet ratio. The primary outcome, 4-year all-cause mortality, was compared among the platelet indices tertile models. According to MPV, platelet count, and MPV/platelet ratio tertile models, there was a trend of higher 4-year mortality for the lower and upper tertiles in comparison to the middle tertiles. However, only the admission MPV/platelet ratio tercile model was statistically significant for predicting the 4-year mortality. The mortality rate of the highest MPV/platelet (48/207 (23%)) and the lowest (41/206 (20%)) tertiles were significantly higher than the middle tertile (19/206 (9%)), p = 0.0004 by the chi-squared test. After adjusting for Global Registry of Acute Coronary Events, the patients in the combined first and third MPV/P tertiles had higher mortality in reference to those in the middle MPV/P tercile (hazard ratio 1.951, confidence interval 1.032-3.687, and p < 0.0396). Our novel finding is that the MPV/platelet ratio is superior to the MPV alone in predicting long-term mortality after NSTEMI. We suggest that using this ratio will magnify any existing relationship between platelet indices and mortality post-NSTMI. Further studies are needed to confirm our finding.
Bian Y, Jin Q, He J, Ngo T, Bae O, Xing L Cell Biol Toxicol. 2024; 40(1):67.
PMID: 39110362 PMC: 11306309. DOI: 10.1007/s10565-024-09908-y.
Modifying platelets at their birth: anti-thrombotic therapy without haemorrhage.
Feely C, Kaushal N, DAvino P, Martin J Front Pharmacol. 2024; 15:1343896.
PMID: 38562457 PMC: 10982340. DOI: 10.3389/fphar.2024.1343896.
Hassan M, Abdayem C, El Daouk S, Matar B Cureus. 2024; 16(3):e55401.
PMID: 38562344 PMC: 10984368. DOI: 10.7759/cureus.55401.
Ma L, Han Q, Sun F, Zhu K, Sun Q Int J Gen Med. 2023; 16:3985-3994.
PMID: 37674583 PMC: 10479580. DOI: 10.2147/IJGM.S416817.
Liu X, Yu S, Liang T, Chen L, Zhang H Int J Gen Med. 2023; 16:847-858.
PMID: 36895511 PMC: 9990455. DOI: 10.2147/IJGM.S395305.